Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2002

View Archived Issues

Antitumor activity of R-116010 is due to inhibition of all-trans-retinoic acid metabolism

Bivalirudin + abciximab for percutaneous coronary revascularization

Androgen suppression improves outcomes in the radiotherapy of locally advanced prostate cancer

Discovery Labs and Aerogen collaborate on aerosol-delivered surfactants

Genzyme Biosurgery and Myosix to advance autologous cell therapy for heart disease

BioTransplant revises development strategy for Allomune system

Phase III results of CDP-571 in Crohn's disease

TLK-19781 to enter clinic at Telik

Phase II/III Esterom trial completes enrollment

Inhibitors of protein kinase C and/or glycogen synthase kinase-3 in Ortho-McNeil patent

aaiPharma and Tanabe Seiyaku form joint venture

Cubist awarded SBIR grant for anthrax target research

Triangle reacquires product rights from Abbott

New carbapenem antibiotics emerge from Sumitomo R&D

Ortho-McNeil presents novel GnRH antagonists for infertility, prostate disorders, etc.

Selective adenosine A1 agonists for cardiovascular ischemic disorders claimed by GSK

Novel delta-opioid agonists/antagonists identified at Ortho-McNeil

P&G scientists describe novel benzimidazole with antitumor/antiviral activity

Iodinated alkenes with potential as X-ray contrast agents in Nycomed Imaging patent

Novel antithrombin agents prepared and tested at Servier

Prous Science webcasts the Mild Cognitive Impairment (MCI): State-of-the-Art Seminar

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...